CIDARA THERAPEUTICS Reports 22.3% Revenue Increase for Q2 FY2023

August 10, 2023

☀️Earnings Overview

For the second quarter of FY2023 ending June 30 2023, CIDARA THERAPEUTICS ($NASDAQ:CDTX) reported total revenue of USD 7.6 million, a 22.3% increase from the same period of the previous year. Net income for the quarter was USD -12.4 million, an improvement on the result of -13.1 million experienced in the same period of the previous year.


GoodWhale has conducted an in-depth analysis of CIDARA THERAPEUTICS’s financials. According to their Risk Rating, CIDARA THERAPEUTICS is a medium risk investment in terms of both financial and business aspects. After conducting the analysis, GoodWhale has detected two risk warnings in CIDARA THERAPEUTICS’s income sheet and balance sheet. In order to view this information, users must become a registered user on the GoodWhale platform. This will give them access to the detailed risk warnings and allow them to make an informed decision about their investment in the company. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Cidara Therapeutics. More…

    Total Revenues Net Income Net Margin
    84.57 -7.55 -8.9%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Cidara Therapeutics. More…

    Operations Investing Financing
    -1.1 -0.22 26.75
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Cidara Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    67.99 52.57 0.17
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Cidara Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    46.6% -9.7%
    FCF Margin ROE ROA
    -1.6% -24.3% -7.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The competition in the market for drugs to treat obesity is heating up.

    However, it faces stiff competition from Rhythm Pharmaceuticals Inc, Akeso Inc, and Poxel SA, who are all working on their own new drugs to treat obesity. The race is on to see who can develop the most effective and safe drug to help people lose weight and keep it off.

    – Rhythm Pharmaceuticals Inc ($NASDAQ:RYTM)

    The company’s market cap is $1.3 billion and its ROE is -55.93%. The company is engaged in the development and commercialization of therapies for the treatment of genetic disorders. The company’s products include Setrusumab, which is used to treat patients with hereditary angioedema; and Firdapse, which is used to treat patients with Lambert-Eaton myasthenic syndrome.

    – Akeso Inc ($SEHK:09926)

    As of 2022, Akeso Inc has a market cap of 25.19B and a Return on Equity of -32.08%. The company is a healthcare services company that provides services to patients with chronic conditions.

    – Poxel SA ($LTS:0RA2)

    Poxel SA is a pharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of diabetes and other metabolic diseases. The company has a market capitalization of 44.51 million as of 2022 and a return on equity of -705.2%. The company’s products include Imeglimin, which is in Phase III clinical development for the treatment of type 2 diabetes, and PXL065, which is in Phase II clinical development for the treatment of type 2 diabetes and non-alcoholic steatohepatitis.


    Cidara Therapeutics is a promising investment opportunity, with revenue for the second quarter of FY2023 increasing 22.3% from the previous year to USD 7.6 million. Despite a net income loss of -12.4 million for the quarter, this is an improvement compared to the previous year, indicating a positive trend. Cidara Therapeutics has potential to provide investors with solid returns in the long run and is worth considering for those looking to diversify their portfolios.

    Recent Posts

    Leave a Comment